Perlegen Sciences, Inc. and SC Liver Research Consortium to Collaborate on Interferon Response in Hepatitis C Patients

MOUNTAIN VIEW, Calif. & SAN DIEGO--(BUSINESS WIRE)--Perlegen Sciences, Inc., and the SC Liver Research Consortium (SCLRC), announced today a collaboration to discover genetic variations that predict which patients with hepatitis C (HCV) are most likely to benefit from treatment. The parties will conduct large scale genetic studies on samples from hundreds of patients with HCV who have been treated, successfully and unsuccessfully, with interferon alfa and ribavirin, the current standard of care for this disease.